Msefsl

CLOSE X

Risk Disclosures on Derivatives

>9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
>On an average, loss makers registered net trading loss close to ₹ 50,000.
>Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
>Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.

WOCKHARDT LTD.

NSE : WOCKPHARMABSE : 532300ISIN CODE : INE049B01025Industry : Pharmaceuticals & DrugsHouse : Wockhardt

BSE1496.7537.1 (+2.54 %)

PREV CLOSE ( ) 1459.65

OPEN PRICE ( ) 1462.00

BID PRICE (QTY) 0.00 (0)

OFFER PRICE (QTY) 0.00 (0)

VOLUME 31015

TODAY'S LOW / HIGH ( )1462.00 1536.35

52 WK LOW / HIGH ( )918.85 1870

NSE1493.7033.1 (+2.27 %)

PREV CLOSE( ) 1460.60

OPEN PRICE ( ) 1460.60

BID PRICE (QTY) 1493.70 (10289)

OFFER PRICE (QTY) 0.00 (0)

VOLUME 521730

TODAY'S LOW / HIGH( ) 1460.60 1535.40

52 WK LOW / HIGH ( )915 1868.8

BSE NSE

1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 08-07 1999

Management Info

Habil Khorakiwala - Chairman Murtaza Khorakiwala - Managing Director

Registered Office

Address D-4, M. I. D. C,Chikalthana, ,
Chhatrapati Sambhajinagar - (Aurangabad),
Maharashtra-431006

Phone 0240-6632222 / 6694444

Email investorrelations@wockhardt.com

Website www.wockhardt.com

Registrars Details

MUFG Intime India Pvt Ltd.

C 101, 247 Park,LBS Marg,Vikhroli (West),Mumbai

Listing : BSE, NSE

NEWS

28Jul Wockhardt informs about press release
Pursuant to Regulation 30 of Listing Regulations, Wockhardt has informed..

11Jul Wockhardt initiates strategic realignm
Wockhardt is undertaking significant strategic realignment of its US bus..

11Jul Wockhardt informs about press release
Wockhardt has informed that it enclosed Press Release ‘Wockhardt Initiat..

06Jun Wockhardt eyeing to launch new antibio
Wockhardt is eyeing to launch its new antibiotic -- ZAYNICH in second ha..

05Jun Wockhardt informs about investor prese
Pursuant to Regulation 30 of the Securities and Exchange Board of India..

Financials

Rs. in Millions

	QTR Jun 25	ANNUAL 25
Net Profit	690	-120
Gross Profit	690	-120
Operating Profit	1560	3550
Net Sales	4130	14020

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Astrazeneca Pharma I (BSE) 9105.75 (0.80%)	M.Cap ( in Cr)22764.38
Glenmark Pharma (BSE) 2116.25 (3.10%)	M.Cap ( in Cr)59720.75
Gland Pharma (BSE) 1919.35 (2.72%)	M.Cap ( in Cr)31622.52
Dr. Reddy's Lab (BSE) 1293.45 (3.45%)	M.Cap ( in Cr)107952.28
Acutaas Chemicals (BSE) 1504.50 (2.48%)	M.Cap ( in Cr)12317.18

Shareholding Pattern

	PROMOTERS	49.09%
	NON-INSTITUTION	32.6%
	MUTUAL FUNDS/UTI	8.02%
	FI/BANKS/INSURANCE	0.46%
	GOVERNMENT	0.02%
	FII	0%

Mf Holdings

Scheme Name	Hold(%)
Samco Active Moment...	6.08
ITI Focused Fund-Reg(G)	4.86
Tata India Pharma &...	3.67
HDFC Pharma and Hea...	2.98
Tata Small Cap Fund...	2.96
ITI Pharma & Health...	2.91
Union Active Moment...	2.63

Risk Disclosures on Derivatives

Smart Quotes

WOCKHARDT LTD.